BRANDL TALOS advises Sportradar on $ 30 million acquisition of XLMedia PLC’s North American business

Press release • Venture Capital & Start Ups from Thomas Talos, Stephan Strass

BRANDL TALOS advised its longstanding client Sportradar on the acquisition of the key assets of XLMedia PLC’s North American business.

The transaction was signed on 21 October 2024 and, after satisfaction of certain customary conditions, completed on 13 November 2024.

XLMedia PLC is a sports digital media company that operated various publishing assets across a wide variety of industry verticals. Following the sale of its European business earlier this year, XLMedia now sold its remaining North American media assets to Sportradar.

The BRANDL TALOS team was led by Thomas Talos and Stephan Strass. Bryan Cave (Douglas Mishkin) and Adelman Matz (Sarah Matz, Sebastian Hoskins, Sarah Sanchez) advised on US law aspects.

XLMedia was advised by Ashurst LLP (Markjan van Schaardenburgh, Daniel Hobbs).

Sportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports, media and betting industries, the company provides sports federations, news media, consumer platforms and sports betting operators with a best-in-class range of solutions to help grow their business. As the trusted partner of organizations like the ATP, NBA, NHL, MLB, NASCAR, UEFA, FIFA and Bundesliga, Sportradar covers close to a million events annually across all major sports. With deep industry relationships and expertise, Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocacy for an integrity-driven environment for all involved.

The team

Thomas Talos

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 11
            [filter] => raw
        )

)

Partner / Capital Markets, Corporate Law & Transactions, Gaming & Entertainment

Thomas founded the firm in 2000 together with Ernst Brandl. He is co-publisher of the commentary on the EU Merger Act and (co-)author of numerous publications.

University of Vienna, Faculty of Law (Mag. iur. 1991, Dr. iur. 1994)
University of Virginia, School of Law (LL.M. 1994)

Stephan Strass

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 11
            [filter] => raw
        )

)

Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience

Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)

Latest insights into
Venture Capital & Start Ups

BRANDL TALOS advises Graph Therapeutics on USD 3.1 million pre-seed financing round

Press release • Venture Capital & Start Ups from Stephan Strass, Lara Präthaler

Graph Therapeutics, a next-generation techbio company, has successfully closed a USD 3.1 million pre-seed financing round. The round is led by Squareone and Merantix Capital, with participation from NAVEC Investment Management and strategic angel investors such as the Atomico Angel Program.

BRANDL TALOS advised Springtime and its Founders on growth equity investment from Scottish Equity Partners

Press release • Venture Capital & Start Ups from Roman Rericha, Adrian Zuschmann, Joseph Gstöttner, Daniel Habich

Springtime Technologies, a leading provider of AI-driven accounts payable automation software, has received a significant growth equity investment from Scottish Equity Partners (SEP), one of Europe's most respected growth equity firms. This strategic partnership marks an exciting new chapter in Springtime's 20-year journey of empowering enterprises with innovative solutions for financial operations.

BRANDL TALOS advised DirectSens on the sale of its market-leading LactoSens® biosensor technology to Kerry Group

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass

Founded in 2013 in Vienna by Christoph Sygmund, Roman Kittl, Roland Ludwig, Wolfgang Harreither and Alfons Felice as a spinoff of BOKU University, DirectSens specializes in developing biosensors, including LactoSens®, a rapid lactose detection tool. The acquisition of LactoSens® by Kerry Group reflects DirectSens' success in developing cutting-edge biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes.